Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $9.09 million. The enterprise value is $7.96 million.
Important Dates
The next estimated earnings date is Wednesday, May 21, 2025, before market open.
Earnings Date | May 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
SLXN has 8.41 million shares outstanding.
Current Share Class | 8.41M |
Shares Outstanding | 8.41M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 5.91% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.25 |
P/TBV Ratio | 12.57 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85
Current Ratio | 3.85 |
Quick Ratio | 3.64 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -452.67 |
Financial Efficiency
Return on equity (ROE) is -116.66% and return on invested capital (ROIC) is -73.07%.
Return on Equity (ROE) | -116.66% |
Return on Assets (ROA) | -62.13% |
Return on Invested Capital (ROIC) | -73.07% |
Return on Capital Employed (ROCE) | -195.11% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | 0.11 |
52-Week Price Change | n/a |
50-Day Moving Average | 1.21 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 45.24 |
Average Volume (20 Days) | 5,213,775 |
Short Selling Information
The latest short interest is 424,328, so 5.04% of the outstanding shares have been sold short.
Short Interest | 424,328 |
Short Previous Month | 976,476 |
Short % of Shares Out | 5.04% |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -1.36M |
Pretax Income | n/a |
Net Income | -1.36M |
EBITDA | -1.36M |
EBIT | -1.36M |
Earnings Per Share (EPS) | -$81.80 |
Full Income Statement Balance Sheet
The company has $788,000 in cash and n/a in debt, giving a net cash position of $788,000 or $0.09 per share.
Cash & Cash Equivalents | 788,000 |
Total Debt | n/a |
Net Cash | 788,000 |
Net Cash Per Share | $0.09 |
Equity (Book Value) | 696,000 |
Book Value Per Share | 4.67 |
Working Capital | 687,000 |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$794,000 and capital expenditures -$5,000, giving a free cash flow of -$799,000.
Operating Cash Flow | -794,000 |
Capital Expenditures | -5,000 |
Free Cash Flow | -799,000 |
FCF Per Share | -$0.09 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -15.49% |
FCF Yield | -9.13% |
Analyst Forecast
The average price target for SLXN is $5.00, which is 362.62% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $5.00 |
Price Target Difference | 362.62% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -61.90% |
Stock Forecasts Stock Splits
The last stock split was on November 29, 2024. It was a reverse split with a ratio of 0.1111111:1.
Last Split Date | Nov 29, 2024 |
Split Type | Reverse |
Split Ratio | 0.1111111:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |